Latest News

Publications

mBio-2020-Morrissette-e02310-20.full_

October 1, 2020

A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients

Madeleine Morrissette, Norman Pitt, Antonio González, Philip Strandwitz, Mariaelena Caboni, Alison W. Rebman, Rob Knight, Anthony D’Onofrio, John N. Aucott, Mark J. Soloski, Kim Lewis
s41598-020-59600-4

March 2, 2020

Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31

Venkata Raveendra Pothineni, Hari-Hara S. K. Potula, Aditya Ambati, Venkata Vamsee Aditya Mallajosyula, Brindha Sridharan, Mohammed Inayathullah, Mohamed Sohail Ahmed, and Jayakumar Rajadas
liegner

May 30, 2019

Disulfiram (Tetraethylthiuram Disulfide) in the Treatment of Lyme Disease and Babesiosis: Report of Experience in Three Cases

By Kenneth Liegner
shor

December 16, 2019

Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group

By Samuel Shor, Christine Green, Beatrice Szantyr, Steven Philips, Kenneth Liegner, Joseph Burrascano Jr., Robert Bransfield, Elizabeth L. Maloney
barth

November 16, 2009

Ineffectiveness of tigecycline against persistent Borrelia burgdorferi

By Barthold SW, Hodzic E, Imai DM, Feng S, Yang X, Luft BJ
nocton

January 27, 1994

Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis

By Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC
04-21-2021

Persistent Lyme Symptoms: A Survey of RI patients

04-20-2021

A Board of Education Member on Lyme in Schools

04-17-2021

Permethrin Susceptibility for Blacklegged Ticks on Shelter Island

04-16-2021

Gut Microbiome Impacts Sleep Quality

04-16-2021

Early Results from First-In-U.S. Trial of CRISPR-Edited Immune Cells for Cancer Patients Suggest Safety of Approach - Penn Medicine

04-16-2021

Positive results in first-in-U.S. trial of CRISPR-edited immune cells | Penn Today